RGEN Earnings Prediction
The chart below shows how RGEN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RGEN sees a -0.55% change in stock price 10 days leading up to the earnings, and a +3.64% change 10 days following the report. On the earnings day itself, the stock moves by +5.16%. This data can give you a slight idea of what to expect for the next quarter's release.
RGEN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
154.87M
9.69%
0.52%
Gross Margin
50.99%
21.46%
1.67%
Operating Margin
-2.76%
67.27%
-222.67%
Net Margin
-0.42%
-103.26%
-119.44%
EPS
-0.01
-103.12%
-116.67%
No Data Available
RGEN Earnings Analysis
Repligen Corp Corporation (RGEN.O) Earnings Conference Call
Positive
Sales and Order Growth: 10% year-over-year sales growth and 6% order growth, with orders pacing above sales by 4%.
CDMO Revenue and Order Growth: CDMO revenues and orders grew approximately 20% year-over-year, with sales back to 2022 levels and order intake year-to-date at high single digits.
Consumable Revenue Recovery: Consumable revenues were up 10% year-over-year, with orders at the highest level since Q1 of 2022, indicating a strong recovery in demand.
Record Revenue Growth: New modalities achieved record revenue growth of over 20% year-over-year, with orders also showing low double-digit growth compared to Q3 of 2023.
Q3 Adjusted Net Income Growth: Adjusted net income for Q3 was $24 million, up nearly $11 million versus last year, driven by a significant increase in adjusted operating income.
Negative
China Revenue Decline: 1. Declining Revenue from China: Revenue from China decreased by approximately 50% year-over-year, contributing only 3% to total business in Q3 2024, indicating a significant market headwind.
Stagnant Year-to-Date Revenue: 2. Flat Year-to-Date Revenue: Year-to-date revenue of $467 million was flat compared to the previous year, highlighting stagnation in growth despite expectations for improvement.
Operating Margin Decline: 3. Operating Margin Pressure: The implied midpoint guidance for Q4 suggests a drop in operating margin from Q3, primarily due to a negative mix impact from higher material costs and lower-margin product sales.
Restructuring Charges Overview: 4. Restructuring Charges: The company incurred nearly $3 million in restructuring charges during Q3, indicating ongoing cost management challenges and the need for operational adjustments.
Biotech Funding Decline: 5. Emerging Biotech Weakness: Emerging biotech funding has declined significantly, with clinical trial starts down by 20-25% year-over-year, posing risks to future revenue growth in this segment.
RGEN FAQs
How does RGEN typically perform around its earnings report dates?
Is Repligen Corporation (RGEN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RGEN Earning Call Sentiment
Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
RGEN.O
-2.84%Positive
The earnings call summary reveals strong financial performance with revenue and profit growth, increased margins, and a healthy cash position. Despite weaker guidance, the Q&A highlights positive industry health, order growth, and strategic focus on M&A and new modalities. The absence of shareholder return plans is a neutral factor, and the lack of market cap data means the stock's reaction is uncertain. Overall, the strong financial metrics and optimistic future outlook suggest a positive stock price movement of 2% to 8%.
